Gauss & Selux Announces First Full-Home Rapid Coronavirus Trial

Gauss, a computer vision startup, and Celtlex, a biotech company that works on diagnostics, are announcing the first rapid COVID-19 test that can be performed entirely by people at home without being included in the lab.

Why it matters: Experts agree that the US still needs more extensive testing to prevent the coronovirus epidemic. An antigen test that can be performed rapidly at home and provide results can help reduce test delays and allow people to find out if they differ due to COVID-19 infection need to.

how it works: In the antigen test, which was developed by Celllex, a user would take nasal inflammation in both nostrils, and then place the swab in a small vial filled with a buffer solution.

  • Four drops from the tube Is kept fast Test cassettes, and test lines will exhibit varying intensities, which will be based on how much virus is in the sample.
  • After this, users will take a photo of Rapid Test, and Gauss’s app will use AI to give back Results – All within 15 minutes.

Of comment: While other rapid diagnostics have been developed that allow users to test themselves at home, those earlier methods still required people to send in samples to a laboratory or health facility for processing.

  • The Guas / Celllex diagnostic will be the first test that can be performed to complete at home.
  • James Lee, CEO of Cellex, says the test shows about 90% sensitivity – how often a test produces a positive result – compared to PCR tests, and about 100% specificity, or how often it produces a true negative result. is.

The key to COVID-19 epidemic management is that it is a tool that will allow people to self-monitor and self-isolate.

– James Lee

What to see: Does the FDA give the new test an Emergency Use Authority, which will allow it to market more quickly.

  • There is also the question of price, although Lee says that “our goal is to make this assay as widely available as possible.”

Bottom-line: Quick and easy at-home tests certainly help reduce the prevalence of COVID-19, and they explain how the epidemic has accelerated the arrival of distributed medicine.